berberine has been researched along with Atherogenesis in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a meta-analysis to evaluate the clinical efficacy of berberine (BBR) in treating acute ischemic stroke (AIS), explore its anti-inflammatory effects, and assess its potential applications for AIS patients." | 9.41 | Effects of adjuvant berberine therapy on acute ischemic stroke: A meta-analysis. ( Chen, B; Harkare, HV; Huang, B; Luo, D; Ma, T; Pan, J; Shi, S; Song, Y; Sun, S; Wang, L; Yu, B, 2023) |
| "Atherosclerosis is the primary cause of many cardiovascular diseases, and an increasing number of studies have shown that berberine could delay plaque formation and development." | 9.22 | Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies. ( Guo, Q; Jia, D; Liu, M; Shi, L; Wu, A; Yang, R; Yu, H; Zhang, D; Zhang, X; Zhao, M, 2022) |
| " Berberine is the main alkaloid of Coptis Chinensis, and, recent researches showed that berberine had the effect of anti-atherosclerosis." | 8.86 | Advance of studies on anti-atherosclerosis mechanism of berberine. ( Liu, LT; Wang, J; Wu, M, 2010) |
| "Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis." | 8.02 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. ( Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| "Berberine (BBR) is an effective component of Huanglian and has shown to attenuate atherosclerosis (AS); however, the detailed mechanism of BBR-mediated protective actions against AS remains elusive." | 7.96 | Berberine Attenuates Arterial Plaque Formation in Atherosclerotic Rats with Damp-Heat Syndrome via Regulating Autophagy. ( Huang, Y; Ke, X; Li, L; Lin, F; Song, Y; Xin, F; Xu, L; Zeng, Z; Zhang, Y, 2020) |
| "Berberine (BBR) has long been used for treating bacterial diarrhea due to its antimicrobial effect and is currently used to treat obesity, diabetes, hyperlipemia and atherosclerosis." | 7.88 | Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. ( Geng, J; Hu, J; Hu, T; Jiang, Y; Li, J; Liu, S; Shi, Y; Wang, B; Yan, W, 2018) |
| "Berberine (BBR) possesses significant anti-atherosclerosis properties." | 7.88 | Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction. ( Cui, X; Liu, Z; Wan, Q; Yang, Y, 2018) |
| " Berberine is used to treat obesity, diabetes and atherosclerosis." | 7.88 | Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe ( Dong, L; Hu, Y; Liu, T; Shen, X; Weng, S; Zhang, D; Zhu, H; Zhu, J; Zhu, L, 2018) |
| "Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression." | 7.78 | The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. ( Bian, H; Chang, XX; Gao, X; Xia, MF; Xu, Q; Yan, HM; Zhu, TF, 2012) |
| "We conclude that berberine reduces oxidative stress and vascular inflammation, and suppresses atherogenesis via a mechanism that includes stimulation of AMPK-dependent UCP2 expression." | 7.77 | Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. ( Liang, B; Shirwany, N; Wang, Q; Zhang, M; Zhu, Y; Zou, MH, 2011) |
| "Berberine is a natural isoquinoline alkaloid extracted from Coptis chinensis that has a wide range of pharmacological effects." | 6.53 | The Role of Berberine in the Multi-Target Treatment of Senile Dementia. ( Chen, S; Guo, Y; Huang, M; Liang, Y, 2016) |
| "Diabetic atherosclerosis is characterized by hyperglycemia, hyperinsulinemia, and dyslipidemia." | 5.72 | Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE ( Hu, C; Ma, C; Man, B; Xiang, J; Yang, G; Yang, S, 2022) |
| " It has been reported that 8-cetylberberine (8-BBR-C16) has increased anti-microbial property in vivo and a higher bioavailability in hamsters." | 5.46 | Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE ( Feng, M; Hu, Y; Li, X; Ma, H; Xiao, Y; Ye, X; Zhou, X; Zou, Z, 2017) |
| "We conducted a meta-analysis to evaluate the clinical efficacy of berberine (BBR) in treating acute ischemic stroke (AIS), explore its anti-inflammatory effects, and assess its potential applications for AIS patients." | 5.41 | Effects of adjuvant berberine therapy on acute ischemic stroke: A meta-analysis. ( Chen, B; Harkare, HV; Huang, B; Luo, D; Ma, T; Pan, J; Shi, S; Song, Y; Sun, S; Wang, L; Yu, B, 2023) |
| "Atherosclerosis is the primary cause of many cardiovascular diseases, and an increasing number of studies have shown that berberine could delay plaque formation and development." | 5.22 | Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies. ( Guo, Q; Jia, D; Liu, M; Shi, L; Wu, A; Yang, R; Yu, H; Zhang, D; Zhang, X; Zhao, M, 2022) |
| " Berberine has been used to treat obesity, diabetes mellitus, atherosclerosis, and metabolic diseases in China." | 5.05 | Effects of Berberine on the Gastrointestinal Microbiota. ( Chen, F; Liao, Y; Sun, X; Wang, L; Wu, X; Wu, Z; Yang, R; Zhang, L; Zhu, Z, 2020) |
| " Berberine is the main alkaloid of Coptis Chinensis, and, recent researches showed that berberine had the effect of anti-atherosclerosis." | 4.86 | Advance of studies on anti-atherosclerosis mechanism of berberine. ( Liu, LT; Wang, J; Wu, M, 2010) |
| "Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis." | 4.02 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. ( Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| "Berberine (BBR) is an effective component of Huanglian and has shown to attenuate atherosclerosis (AS); however, the detailed mechanism of BBR-mediated protective actions against AS remains elusive." | 3.96 | Berberine Attenuates Arterial Plaque Formation in Atherosclerotic Rats with Damp-Heat Syndrome via Regulating Autophagy. ( Huang, Y; Ke, X; Li, L; Lin, F; Song, Y; Xin, F; Xu, L; Zeng, Z; Zhang, Y, 2020) |
| "Berberine (BBR) possesses significant anti-atherosclerosis properties." | 3.88 | Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction. ( Cui, X; Liu, Z; Wan, Q; Yang, Y, 2018) |
| "Berberine (BBR) has long been used for treating bacterial diarrhea due to its antimicrobial effect and is currently used to treat obesity, diabetes, hyperlipemia and atherosclerosis." | 3.88 | Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. ( Geng, J; Hu, J; Hu, T; Jiang, Y; Li, J; Liu, S; Shi, Y; Wang, B; Yan, W, 2018) |
| " Berberine is used to treat obesity, diabetes and atherosclerosis." | 3.88 | Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe ( Dong, L; Hu, Y; Liu, T; Shen, X; Weng, S; Zhang, D; Zhu, H; Zhu, J; Zhu, L, 2018) |
| "Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression." | 3.78 | The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. ( Bian, H; Chang, XX; Gao, X; Xia, MF; Xu, Q; Yan, HM; Zhu, TF, 2012) |
| "We conclude that berberine reduces oxidative stress and vascular inflammation, and suppresses atherogenesis via a mechanism that includes stimulation of AMPK-dependent UCP2 expression." | 3.77 | Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. ( Liang, B; Shirwany, N; Wang, Q; Zhang, M; Zhu, Y; Zou, MH, 2011) |
| "Berberine is a bioactive isoquinoline alkaloid compound extracted from various medicinal plants, such as Barberry." | 2.82 | Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. ( Hashemy, SI; Nourizadeh, N; Saburi, E; Vazifeh Mostaan, L, 2022) |
| "Berberine is a natural isoquinoline alkaloid extracted from Coptis chinensis that has a wide range of pharmacological effects." | 2.53 | The Role of Berberine in the Multi-Target Treatment of Senile Dementia. ( Chen, S; Guo, Y; Huang, M; Liang, Y, 2016) |
| "Diabetic atherosclerosis is characterized by hyperglycemia, hyperinsulinemia, and dyslipidemia." | 1.72 | Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE ( Hu, C; Ma, C; Man, B; Xiang, J; Yang, G; Yang, S, 2022) |
| "Atherosclerosis is a chronic inflammation condition resulting from the interaction between lipoproteins, monocyte-derived macrophages, T lymphocytes, and other cellular elements in the arterial wall." | 1.56 | Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway. ( Chen, Y; Ding, XS; Feng, N; Feng, XF; Liu, F; Yang, LC; Yang, XJ; Zhu, SX, 2020) |
| " It has been reported that 8-cetylberberine (8-BBR-C16) has increased anti-microbial property in vivo and a higher bioavailability in hamsters." | 1.46 | Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE ( Feng, M; Hu, Y; Li, X; Ma, H; Xiao, Y; Ye, X; Zhou, X; Zou, Z, 2017) |
| " Derivatives of BBR have been suggested to have enhanced bioavailability compared to BBR." | 1.40 | Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice. ( Cao, J; Chen, J; Fang, L; Li, Y; Liu, B; Meng, S; Sun, Y; Wang, Y; Zhou, Q, 2014) |
| " In the present study, we aimed to investigate the effect of berberine combined with atorvastatin on LOX‑1 and explore the underlying molecular mechanism involved." | 1.40 | Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages. ( Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y, 2014) |
| "Berberine (BBR) is a botanical alkaloid that has been reported to have effects in cardiovascular diseases; however, the mechanisms involved are not yet fully understood." | 1.40 | The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1. ( Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y, 2014) |
| "Rats with renal artery stenosis were randomly assigned to two groups (n = 6 each) - ARD, or ARD+BBR - according to diet alone or in combination with BBR." | 1.39 | Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFκB signaling pathway in rats. ( Cao, CC; Chen, W; Chen, X; Huang, WJ; Liu, L; Miao, GG; Wan, X; Xie, HG; Zhang, Q; Zhao, Y, 2013) |
| "Berberine can inhibit the expression of LOX-1 and promote the expression of SR-BI in macrophage-derived foam cells." | 1.36 | Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. ( Fang, X; Guan, J; Guan, S; Li, W; Wang, B, 2010) |
| "Berberine inhibits COX-2 expression via the ERK1/2 signalling pathway and, possibly, at a high dosage via the JNK pathway." | 1.35 | Biochemical pathways in the antiatherosclerotic effect of berberine. ( Guo, Y; Jiang, X; Li, FM; Wang, L; Wang, QZ; Zuo, YF, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (11.76) | 29.6817 |
| 2010's | 19 (55.88) | 24.3611 |
| 2020's | 11 (32.35) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, D | 1 |
| Zhang, X | 2 |
| Guo, Q | 1 |
| Yang, R | 2 |
| Yu, H | 1 |
| Zhao, M | 1 |
| Shi, L | 1 |
| Liu, M | 1 |
| Wu, A | 1 |
| Zhang, D | 2 |
| Man, B | 1 |
| Hu, C | 1 |
| Yang, G | 1 |
| Xiang, J | 1 |
| Yang, S | 1 |
| Ma, C | 1 |
| Nourizadeh, N | 1 |
| Vazifeh Mostaan, L | 1 |
| Saburi, E | 1 |
| Hashemy, SI | 1 |
| Luo, D | 1 |
| Yu, B | 1 |
| Sun, S | 1 |
| Chen, B | 1 |
| Harkare, HV | 1 |
| Wang, L | 6 |
| Pan, J | 1 |
| Huang, B | 1 |
| Song, Y | 2 |
| Ma, T | 1 |
| Shi, S | 1 |
| Yang, XJ | 1 |
| Liu, F | 1 |
| Feng, N | 1 |
| Ding, XS | 1 |
| Chen, Y | 1 |
| Zhu, SX | 1 |
| Yang, LC | 1 |
| Feng, XF | 1 |
| Tan, W | 1 |
| Wang, Y | 3 |
| Wang, K | 1 |
| Wang, S | 1 |
| Liu, J | 1 |
| Qin, X | 1 |
| Dai, Y | 1 |
| Wang, X | 1 |
| Gao, X | 2 |
| Ke, X | 1 |
| Huang, Y | 1 |
| Li, L | 1 |
| Xin, F | 1 |
| Xu, L | 1 |
| Zhang, Y | 5 |
| Zeng, Z | 1 |
| Lin, F | 1 |
| Fatahian, A | 1 |
| Haftcheshmeh, SM | 1 |
| Azhdari, S | 1 |
| Farshchi, HK | 1 |
| Nikfar, B | 1 |
| Momtazi-Borojeni, AA | 1 |
| Deng, L | 1 |
| Lin, N | 1 |
| Shi, Y | 2 |
| Chen, J | 2 |
| Zhou, Y | 1 |
| Chen, D | 1 |
| Liu, S | 2 |
| Li, C | 1 |
| Zhang, L | 1 |
| Wu, X | 1 |
| Chen, F | 1 |
| Liao, Y | 1 |
| Zhu, Z | 1 |
| Wu, Z | 1 |
| Sun, X | 1 |
| Li, X | 2 |
| Su, C | 1 |
| Jiang, Z | 1 |
| Yang, Y | 2 |
| Yang, M | 1 |
| Du, Y | 1 |
| Zhang, J | 1 |
| Jiang, J | 1 |
| Hong, B | 1 |
| Zhu, L | 1 |
| Zhu, H | 1 |
| Zhu, J | 1 |
| Weng, S | 1 |
| Dong, L | 1 |
| Liu, T | 1 |
| Hu, Y | 2 |
| Shen, X | 1 |
| Wan, Q | 1 |
| Liu, Z | 1 |
| Cui, X | 1 |
| Zhu, TL | 1 |
| Yang, B | 1 |
| Guo, YS | 1 |
| Ji, YS | 1 |
| Li, XY | 1 |
| Geng, C | 1 |
| Hidru, TH | 1 |
| Zhi, L | 1 |
| Tao, M | 1 |
| Zou, L | 1 |
| Chen, C | 1 |
| Li, H | 1 |
| Liu, Y | 2 |
| Hu, J | 1 |
| Geng, J | 1 |
| Hu, T | 1 |
| Wang, B | 2 |
| Yan, W | 1 |
| Jiang, Y | 1 |
| Li, J | 1 |
| Wan, X | 1 |
| Chen, X | 1 |
| Liu, L | 1 |
| Zhao, Y | 1 |
| Huang, WJ | 1 |
| Zhang, Q | 1 |
| Miao, GG | 1 |
| Chen, W | 1 |
| Xie, HG | 1 |
| Cao, CC | 1 |
| Chi, L | 2 |
| Peng, L | 2 |
| Hu, X | 2 |
| Pan, N | 2 |
| Zimetti, F | 1 |
| Adorni, MP | 1 |
| Ronda, N | 1 |
| Gatti, R | 1 |
| Bernini, F | 1 |
| Favari, E | 1 |
| Cao, J | 1 |
| Fang, L | 1 |
| Liu, B | 1 |
| Zhou, Q | 1 |
| Sun, Y | 1 |
| Li, Y | 2 |
| Meng, S | 2 |
| Seo, CS | 1 |
| Kim, OS | 1 |
| Kim, JH | 1 |
| Shin, HK | 1 |
| Huang, M | 1 |
| Chen, S | 1 |
| Liang, Y | 1 |
| Guo, Y | 2 |
| Feng, M | 1 |
| Zou, Z | 1 |
| Zhou, X | 1 |
| Ma, H | 1 |
| Xiao, Y | 1 |
| Ye, X | 1 |
| Kou, JY | 1 |
| Zhong, ZY | 1 |
| Jiang, YQ | 1 |
| Li, XS | 1 |
| Han, XB | 1 |
| Liu, ZN | 1 |
| Tian, Y | 1 |
| Yang, LM | 1 |
| Wang, QZ | 1 |
| Li, FM | 1 |
| Jiang, X | 1 |
| Zuo, YF | 1 |
| Chen, FL | 1 |
| Yang, ZH | 1 |
| Li, LX | 1 |
| Liang, WC | 1 |
| Wang, XC | 1 |
| Zhou, WB | 1 |
| Yang, YH | 1 |
| Hu, RM | 1 |
| Wu, M | 2 |
| Wang, J | 2 |
| Li, K | 1 |
| Yao, W | 1 |
| Zheng, X | 1 |
| Liao, K | 1 |
| Huang, Z | 1 |
| Chen, T | 1 |
| Wang, C | 1 |
| Liu, LT | 1 |
| Guan, S | 1 |
| Li, W | 1 |
| Guan, J | 1 |
| Fang, X | 1 |
| Wang, Q | 1 |
| Zhang, M | 1 |
| Liang, B | 1 |
| Shirwany, N | 1 |
| Zhu, Y | 1 |
| Zou, MH | 1 |
| Chang, XX | 1 |
| Yan, HM | 1 |
| Xu, Q | 1 |
| Xia, MF | 1 |
| Bian, H | 1 |
| Zhu, TF | 1 |
9 reviews available for berberine and Atherogenesis
| Article | Year |
|---|---|
Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies.
Topics: Animals; Atherosclerosis; Berberine; Lipoproteins, HDL; Lipoproteins, LDL; Mice; Mice, Knockout, Apo | 2022 |
Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review.
Topics: Anti-Inflammatory Agents; Antioxidants; Aryldialkylphosphatase; Atherosclerosis; Berberine; Choleste | 2022 |
Effects of adjuvant berberine therapy on acute ischemic stroke: A meta-analysis.
Topics: Atherosclerosis; Berberine; Carotid Intima-Media Thickness; Humans; Ischemic Stroke; Stroke; Triglyc | 2023 |
Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies.
Topics: Atherosclerosis; Berberine; Cholesterol, LDL; Endothelial Cells; Humans; Receptors, LDL | 2020 |
Effects of Berberine on the Gastrointestinal Microbiota.
Topics: Animals; Atherosclerosis; Berberine; China; Gastrointestinal Microbiome; Humans; Insulin Resistance | 2020 |
Sonodynamic therapy: A potential treatment for atherosclerosis.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Atherosclerosis; Berberine; Cell Death; Chal | 2018 |
The Role of Berberine in the Multi-Target Treatment of Senile Dementia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Berberine; Cholinesterase Inhibit | 2016 |
[Advance on study in anti-atherosclerosis mechanism of berberine].
Topics: Animals; Atherosclerosis; Berberine; Blood Glucose; Coptis; Drugs, Chinese Herbal; Humans; Myocytes, | 2008 |
Advance of studies on anti-atherosclerosis mechanism of berberine.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Berberine; Blood Glucose; Blood Pressure; Humans | 2010 |
25 other studies available for berberine and Atherogenesis
| Article | Year |
|---|---|
Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Diabetes Mellitus; Glucose; Inflammation; Kr | 2022 |
Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subf | 2020 |
Improvement of Endothelial Dysfunction of Berberine in Atherosclerotic Mice and Mechanism Exploring through TMT-Based Proteomics.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Berberine; Endothelium, Vascular; Fatty Acids; G | 2020 |
Berberine Attenuates Arterial Plaque Formation in Atherosclerotic Rats with Damp-Heat Syndrome via Regulating Autophagy.
Topics: Administration, Oral; Animals; Atherosclerosis; Autophagy; Berberine; Disease Models, Animal; Dose-R | 2020 |
Berberine inhibits proliferation and apoptosis of vascular smooth muscle cells induced by mechanical stretch via the PDI/ERS and MAPK pathways.
Topics: Animals; Apoptosis; Atherosclerosis; Berberine; Cell Proliferation; Cells, Cultured; China; Endoplas | 2020 |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.
Topics: Animals; Atherosclerosis; Berberine; Choline; Diet; Disease Models, Animal; Disease Susceptibility; | 2021 |
Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; Berberine; Cytokines; Di | 2018 |
Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.
Topics: Animals; Atherosclerosis; Berberine; Cytokines; Down-Regulation; Endothelial Cells; Human Umbilical | 2018 |
[Effects of the Traditional Chinese Medicine berberine on antiatheroscloresis and antioxidant activities in hyperlipoidemic model rats].
Topics: Animals; Antioxidants; Atherosclerosis; Berberine; Cholesterol; Drugs, Chinese Herbal; Glutathione P | 2017 |
Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Cytokines; Denaturing Gradient Gel Electroph | 2018 |
Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFκB signaling pathway in rats.
Topics: Animals; Antioxidants; Atherosclerosis; Berberine; Biomarkers; Fibrosis; Inflammation; Male; NF-kapp | 2013 |
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Berberine; Body Weight; Cells, Cul | 2014 |
The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1.
Topics: Adenylate Kinase; Atherosclerosis; Atorvastatin; Berberine; Cholesterol; Foam Cells; Heptanoic Acids | 2014 |
The natural compound berberine positively affects macrophage functions involved in atherogenesis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Berberine; Cell Membrane; Cells, Cultured; Chemo | 2015 |
Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Cell Line; Humans; Mice; Mice, Knockout | 2014 |
Simultaneous quantification and antiatherosclerosis effect of the traditional Korean medicine, Hwangryunhaedok-tang.
Topics: Animals; Antioxidants; Atherosclerosis; Berberine; Berberine Alkaloids; Biphenyl Compounds; Cell Pro | 2015 |
Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Apolipoproteins E; Atherosclerosis; Berberin | 2017 |
Berberine-sonodynamic therapy induces autophagy and lipid unloading in macrophage.
Topics: Atherosclerosis; Autophagy; Berberine; Cell Survival; Cholesterol; Chromones; Humans; Lipids; Macrop | 2017 |
Biochemical pathways in the antiatherosclerotic effect of berberine.
Topics: Atherosclerosis; Berberine; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Res | 2008 |
Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.
Topics: Anilides; Atherosclerosis; Berberine; Cell Line; Chemokine CCL2; Humans; Hypoglycemic Agents; Interl | 2008 |
Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Berberine; Foam Cells; Macrophages; Mice; Mice, Inbred | 2009 |
Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages.
Topics: Atherosclerosis; Basigin; Berberine; Carcinogens; Cell Line; Dose-Response Relationship, Drug; Human | 2011 |
Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL.
Topics: Atherosclerosis; ATP-Binding Cassette Transporters; Berberine; Blotting, Western; Cell Line; Coptis; | 2010 |
Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2.
Topics: Acetyl-CoA Carboxylase; Aldehydes; AMP-Activated Protein Kinases; Animals; Aorta; Apolipoproteins E; | 2011 |
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
Topics: Animals; Aorta; Apolipoproteins; Atherosclerosis; Berberine; Cholesterol; Cholesterol, LDL; Diet, Hi | 2012 |